Non-Lethal Sequential Individual Monitoring of Viremia in Relation to DNA Vaccination in Fish–Example Using a Salmon Alphavirus DNA Vaccine in Atlantic Salmon Salmo salar

Traditionally, commercial testing for vaccine efficacy has relied on the mass infection of vaccinated and unvaccinated animals and the comparison of mortality prevalence and incidence. For some infection models where disease does not cause mortality this approach to testing vaccine efficacy is not u...

Full description

Bibliographic Details
Published in:Vaccines
Main Authors: Collins, Catherine, Lester, Katherine, Del-Pozo, Jorge, Collet, Bertrand
Format: Text
Language:English
Published: MDPI 2021
Subjects:
Online Access:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922653/
https://doi.org/10.3390/vaccines9020163
id ftpubmed:oai:pubmedcentral.nih.gov:7922653
record_format openpolar
spelling ftpubmed:oai:pubmedcentral.nih.gov:7922653 2023-05-15T15:32:55+02:00 Non-Lethal Sequential Individual Monitoring of Viremia in Relation to DNA Vaccination in Fish–Example Using a Salmon Alphavirus DNA Vaccine in Atlantic Salmon Salmo salar Collins, Catherine Lester, Katherine Del-Pozo, Jorge Collet, Bertrand 2021-02-17 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922653/ https://doi.org/10.3390/vaccines9020163 en eng MDPI http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922653/ http://dx.doi.org/10.3390/vaccines9020163 © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). CC-BY Vaccines (Basel) Article Text 2021 ftpubmed https://doi.org/10.3390/vaccines9020163 2021-03-07T02:26:33Z Traditionally, commercial testing for vaccine efficacy has relied on the mass infection of vaccinated and unvaccinated animals and the comparison of mortality prevalence and incidence. For some infection models where disease does not cause mortality this approach to testing vaccine efficacy is not useful. Additionally, in fish experimental studies on vaccine efficacy and immune response the norm is that several individuals are lethally sampled at sequential timepoints, and results are extrapolated to represent the kinetics of immune and disease parameters of an individual fish over the entire experimental infection period. In the present study we developed a new approach to vaccine testing for viremic viruses in fish by following the same individuals over the course of a DNA vaccination and experimental infection through repeated blood collection and analyses. Injectable DNA vaccines are particularly efficient against viral disease in fish. To date, two DNA vaccines have been authorised for use in fish farming, one in Canada against Infectious Haemorrhagic Necrotic virus and more recently one in Europe against Salmon Pancreatic Disease virus (SPDv) subtype 3. In the current study we engineered and used an experimental DNA vaccine against SPDv subtype 1. We measured viremia using a reporter cell line system and demonstrated that the viremia phase was completely extinguished following DNA vaccination. Differences in viremia infection kinetics between fish in the placebo group could be related to subsequent antibody levels in the individual fish, with higher antibody levels at terminal sampling in fish showing earlier viremia peaks. The results indicate that sequential non-lethal sampling can highlight associations between infection traits and immune responses measured at asynchronous timepoints and, can provide biological explanations for variation in data. Similar to results observed for the SPDv subtype 3 DNA vaccine, the SPDv subtype 1 DNA vaccine also induced an interferon type 1 response after vaccination and ... Text Atlantic salmon Salmo salar PubMed Central (PMC) Canada Vaccines 9 2 163
institution Open Polar
collection PubMed Central (PMC)
op_collection_id ftpubmed
language English
topic Article
spellingShingle Article
Collins, Catherine
Lester, Katherine
Del-Pozo, Jorge
Collet, Bertrand
Non-Lethal Sequential Individual Monitoring of Viremia in Relation to DNA Vaccination in Fish–Example Using a Salmon Alphavirus DNA Vaccine in Atlantic Salmon Salmo salar
topic_facet Article
description Traditionally, commercial testing for vaccine efficacy has relied on the mass infection of vaccinated and unvaccinated animals and the comparison of mortality prevalence and incidence. For some infection models where disease does not cause mortality this approach to testing vaccine efficacy is not useful. Additionally, in fish experimental studies on vaccine efficacy and immune response the norm is that several individuals are lethally sampled at sequential timepoints, and results are extrapolated to represent the kinetics of immune and disease parameters of an individual fish over the entire experimental infection period. In the present study we developed a new approach to vaccine testing for viremic viruses in fish by following the same individuals over the course of a DNA vaccination and experimental infection through repeated blood collection and analyses. Injectable DNA vaccines are particularly efficient against viral disease in fish. To date, two DNA vaccines have been authorised for use in fish farming, one in Canada against Infectious Haemorrhagic Necrotic virus and more recently one in Europe against Salmon Pancreatic Disease virus (SPDv) subtype 3. In the current study we engineered and used an experimental DNA vaccine against SPDv subtype 1. We measured viremia using a reporter cell line system and demonstrated that the viremia phase was completely extinguished following DNA vaccination. Differences in viremia infection kinetics between fish in the placebo group could be related to subsequent antibody levels in the individual fish, with higher antibody levels at terminal sampling in fish showing earlier viremia peaks. The results indicate that sequential non-lethal sampling can highlight associations between infection traits and immune responses measured at asynchronous timepoints and, can provide biological explanations for variation in data. Similar to results observed for the SPDv subtype 3 DNA vaccine, the SPDv subtype 1 DNA vaccine also induced an interferon type 1 response after vaccination and ...
format Text
author Collins, Catherine
Lester, Katherine
Del-Pozo, Jorge
Collet, Bertrand
author_facet Collins, Catherine
Lester, Katherine
Del-Pozo, Jorge
Collet, Bertrand
author_sort Collins, Catherine
title Non-Lethal Sequential Individual Monitoring of Viremia in Relation to DNA Vaccination in Fish–Example Using a Salmon Alphavirus DNA Vaccine in Atlantic Salmon Salmo salar
title_short Non-Lethal Sequential Individual Monitoring of Viremia in Relation to DNA Vaccination in Fish–Example Using a Salmon Alphavirus DNA Vaccine in Atlantic Salmon Salmo salar
title_full Non-Lethal Sequential Individual Monitoring of Viremia in Relation to DNA Vaccination in Fish–Example Using a Salmon Alphavirus DNA Vaccine in Atlantic Salmon Salmo salar
title_fullStr Non-Lethal Sequential Individual Monitoring of Viremia in Relation to DNA Vaccination in Fish–Example Using a Salmon Alphavirus DNA Vaccine in Atlantic Salmon Salmo salar
title_full_unstemmed Non-Lethal Sequential Individual Monitoring of Viremia in Relation to DNA Vaccination in Fish–Example Using a Salmon Alphavirus DNA Vaccine in Atlantic Salmon Salmo salar
title_sort non-lethal sequential individual monitoring of viremia in relation to dna vaccination in fish–example using a salmon alphavirus dna vaccine in atlantic salmon salmo salar
publisher MDPI
publishDate 2021
url http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922653/
https://doi.org/10.3390/vaccines9020163
geographic Canada
geographic_facet Canada
genre Atlantic salmon
Salmo salar
genre_facet Atlantic salmon
Salmo salar
op_source Vaccines (Basel)
op_relation http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922653/
http://dx.doi.org/10.3390/vaccines9020163
op_rights © 2021 by the authors.
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
op_rightsnorm CC-BY
op_doi https://doi.org/10.3390/vaccines9020163
container_title Vaccines
container_volume 9
container_issue 2
container_start_page 163
_version_ 1766363395781558272